PharmaGroup ApS Financials, key figures and credit report
Gross profit 5 561.2 kDKK FY 2025 -39.1% vs 2024
EBIT 2 955.1 kDKK FY 2025 -54.4% vs 2024
Net debt - 208.1 kDKK FY 2025 +44.5% vs 2024
Quick ratio 2.7 FY 2025 -0.2 vs 2024
Income statement (kDKK)
2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 |
| Net sales | ||||
| Gross profit | 2 976.52 | 8 767.73 | 9 138.00 | 5 561.23 |
| Employee benefit expenses | - 241.17 | -1 458.30 | -2 438.00 | -2 390.12 |
| Total depreciation | - 216.00 | - 216.00 | - 216.00 | - 216.00 |
| EBIT | 2 519.35 | 7 093.43 | 6 484.00 | 2 955.11 |
| Other financial income | 126.53 | |||
| Other financial expenses | -1 206.73 | -75.83 | -13.00 | -34.17 |
| Pre-tax profit | 1 312.62 | 7 017.60 | 6 471.00 | 3 047.47 |
| Income taxes | - 295.02 | -1 569.84 | -1 434.00 | - 680.72 |
| Net earnings | 1 017.60 | 5 447.76 | 5 037.00 | 2 366.75 |
Assets (kDKK)
2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Goodwill | 864.00 | 648.00 | 432.00 | 216.00 |
| Intangible assets total | 864.00 | 648.00 | 432.00 | 216.00 |
| Tangible assets total | ||||
| Investments total | ||||
| Long term receivables total | ||||
| Inventories total | ||||
| Current trade debtors | 1 117.53 | 2 052.00 | 1 330.44 | |
| Current amounts owed by group member comp. | 7 529.00 | 4 871.00 | 2 088.89 | |
| Prepayments and accrued income | 42.86 | |||
| Current other receivables | -1.00 | 2.15 | ||
| Short term receivables total | 8 646.52 | 6 922.00 | 3 464.33 | |
| Cash and bank deposits | 1 720.05 | 860.42 | 375.00 | 208.11 |
| Cash and cash equivalents | 1 720.05 | 860.42 | 375.00 | 208.11 |
| Balance sheet total (assets) | 2 584.05 | 10 154.95 | 7 729.00 | 3 888.45 |
Equity and liabilities (kDKK)
2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Share capital | 40.00 | 40.00 | 40.00 | 40.00 |
| Share premium account | 749.02 | |||
| Shares repurchased | 7 200.00 | 5 000.00 | 2 200.00 | |
| Retained earnings | -5 433.37 | -4 985.00 | -2 148.47 | |
| Profit of the financial year | 1 017.60 | 5 447.76 | 5 037.00 | 2 366.75 |
| Shareholders equity total | 1 806.63 | 7 254.39 | 5 092.00 | 2 458.28 |
| Provisions | 190.08 | 142.56 | 95.00 | 47.52 |
| Non-current liabilities total | ||||
| Current trade creditors | 13.75 | 13.75 | 25.00 | 60.62 |
| Current owed to participating | 47.16 | 47.16 | ||
| Short-term deferred tax liabilities | 357.27 | 1 686.55 | 1 481.00 | 728.24 |
| Other non-interest bearing current liabilities | 169.16 | 1 010.53 | 1 037.00 | 593.79 |
| Current liabilities total | 587.34 | 2 758.00 | 2 543.00 | 1 382.65 |
| Balance sheet total (liabilities) | 2 584.05 | 10 154.95 | 7 730.00 | 3 888.45 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated